Fig. 2

Patient-reported outcomes by disease activity. Association of disease activity with PROs and income (a) EuroQoL-5D-3 L,^a (b) Functional Assessment of Chronic Illness Therapy-Fatigue,^b (c) Work Productivity and Activity Impairment-Lupus questionnaire, (d) Annual loss of income. ^a Higher scores on the EuroQoL-5D-3 L indicate better health status. ^b Higher scores on the Functional Assessment of Chronic Illness Therapy-Fatigue indicate lower levels of fatigue. *WPAI total activity impairment: Low disease activity (N = 24); Active disease (N = 24). Patients were considered to have low disease activity if they had a SLEDAI score of ≤ 4 and were receiving a glucocorticoid dose of ≤ 7.5 mg/day; patients were considered to have active disease if they had a SLEDAI score of > 4 or were receiving a glucocorticoid at a dose of > 7.5 mg/day. CI, confidence interval; EQ-5D-3 L, EuroQoL-5D-3 L; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; WPAI, Work Productivity and Activity Impairment questionnaire